Zyprexa Relprevv REMS May Need Revision Following Two Patient Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA investigating reports of two patients who died three to four days after receiving Lilly’s long-acting intramuscular antipsychotic; it is uncertain whether they died from post-injection delirium sedation syndrome.